ENVB — Enveric Biosciences Income Statement
0.000.00%
- $3.64m
- -$2.71m
- 17
- 47
- 11
- 14
Annual income statement for Enveric Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 39.9 | 0 | 0 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 8.15 | — | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 46.2 | 5.62 | 64.6 | 27.4 | 16.4 |
Operating Profit | -6.32 | -5.62 | -64.6 | -27.4 | -16.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.22 | -6.86 | -56.4 | -20 | -17.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.6 | -6.86 | -49 | -18.5 | -17.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.6 | -6.86 | -49 | -18.5 | -17.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.03 | -6.86 | -49 | -18.8 | -17.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -567 | -59.7 | -49.6 | -9.65 | -8.09 |